Novartis India Introduces Otrivin In Nasal Spray Format
Otrivin, indicated for the symptomatic relief of nasal congestion
Novartis India has launched Otrivin in a Nasal Spray format. Otrivin will now be available as a topical nasal decongestant in an easy-to-use direct acting spray format in India.
The company said that Otrivin Nasal Spray will be available over-the-counter (OTC) at chemist stores. It acts directly by constricting the blood vessels in the nasal tissues leading to relief from nasal congestion. Otrivin formulation comprises Xylometazoline 0.1%, and is indicated for the symptomatic relief of nasal congestion due to cold, seasonal and perennial allergic rhinitis and sinusitis.
Vineet Singhal, head of OTC Business Unit at Novartis, said: “A common cold can slow down the pace of life. Otrivin nasal spray will help them manage their common cold symptoms more efficiently through a direct acting solution. It acts locally inside the nose within 2 minutes and works for as long as 10 hours.”
Related Insight
Suppliers Directory
BioBuffer Solutions - Biopharm/Biotech Buffers and Reagents
BioBuffer Solutions is a manufacturer of biological buffers and laboratory reagents intended for use in the biopharm and biotech markets. The staff at BioBuffer Solutions has over 15 years of experience in the manufacturing and quality management of these buffers and reagents. We offer fully traceable custom buffers, reagents and solutions.
Suppliers
Pharmaceutical Development Services - Pharmaceutical, Regulatory and Medical Device Consultancy
Pharmaceutical Development Services (PDS) is a pharmaceutical and regulatory consultancy serving the pharmaceutical, biopharmaceutical, medical device and cosmetic industries. We provide expert advice on drug development and production strategy including the development, supply and regulatory control of new and existing pharmaceutical products.
Suppliers
Sofrigam - Industrial Insulated and Refrigerated Packaging
Sofrigam designs and qualifies isothermal and refrigerated packaging enabling the transport of heat sensitive products in non-refrigerated vehicles.
Suppliers
IQnovate - Contract Medical Affairs Services
The IQnovate Life Science Organization is a contract medical affairs organisation and scientific service provider to the Biopharmaceutical industry. IQnovate also extends a premium advisory service to institutional capital investors on biotech investment strategy.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Reversed-Phase Analysis of Alkylbenzene Sulfonates
Published by Tosoh Bioscience
White Papers
Crystal Characterization of Almatis Tabular Alumina
Published by Phenom World
White Papers
Biomarker Solutions
Published by Randox
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.